Literature DB >> 7290132

Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease.

P L Friedman, E J Brown, S Gunther, R W Alexander, W H Barry, G H Mudge, W Grossman.   

Abstract

Prostaglandins may be important regulators of coronary blood flow. To investigate this possibility, we studied the effect of blockade of prostaglandin synthesis by indomethacin in nine patients with coronary-artery disease. Coronary-sinus blood flow (determined with the thermodilution technique) was recorded, together with mean arterial blood pressure and the myocardial arteriovenous oxygen difference from simultaneously obtained arterial and coronary-sinus blood samples, before and 20 minutes after an intravenous dose of indomethacin (0.5 mg per kilogram of body weight). There were significant increases (P less than 0.05) in mean arterial pressure (from 99 +/- 4 to 118 +/- 5 mm Hg [+/- S.E.M.]), coronary vascular resistance (+73 per cent), and myocardial arteriovenous oxygen difference (from 107 +/- 5 to 138 +/- 4 ml per liter) after indomethacin, but coronary blood flow fell significantly, from 181 +/- 29 to 111 +/- 14 ml per minute (P less than 0.05). Thus, despite an increase in myocardial oxygen demand, coronary blood flow fell and coronary vascular resistance increased. This coronary vasoconstrictor effect may have been due to blockade of vasodilatory prostaglandin synthesis or to a direct drug effect. Whatever the mechanism, indomethacin should be used with caution in patients with severe coronary-artery disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7290132     DOI: 10.1056/NEJM198111123052002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  34 in total

1.  Acute Pericarditis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  Exercise training enhances multiple mechanisms of relaxation in coronary arteries from ischemic hearts.

Authors:  Rachel R Deer; Cristine L Heaps
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-30       Impact factor: 4.733

3.  What We Do When We Suppress Fever.

Authors:  Philip A Mackowiak
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 4.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

Review 5.  The current role of platelet-active drugs in ischaemic heart disease.

Authors:  D M Kerins; G A FitzGerald
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 6.  Local control of skeletal muscle blood flow during exercise: influence of available oxygen.

Authors:  Darren P Casey; Michael J Joyner
Journal:  J Appl Physiol (1985)       Date:  2011-09-01

Review 7.  Control of coronary blood flow by autacoids.

Authors:  E Bassenge
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 8.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 9.  Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications.

Authors:  J Webster
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

10.  Responses of human, monkey and dog coronary arteries in vitro to carbocyclic thromboxane A2 and vasodilators.

Authors:  N Toda
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.